ATE366583T1 - Identifizierung von spezifischen differenziell exprimierten antigenen aus mycobacterium und medizinische verwendung der mycobakteriumproteine rv0068 und rv3407 - Google Patents

Identifizierung von spezifischen differenziell exprimierten antigenen aus mycobacterium und medizinische verwendung der mycobakteriumproteine rv0068 und rv3407

Info

Publication number
ATE366583T1
ATE366583T1 AT00904979T AT00904979T ATE366583T1 AT E366583 T1 ATE366583 T1 AT E366583T1 AT 00904979 T AT00904979 T AT 00904979T AT 00904979 T AT00904979 T AT 00904979T AT E366583 T1 ATE366583 T1 AT E366583T1
Authority
AT
Austria
Prior art keywords
mycobacterium
relates
differentially expressed
present
identification
Prior art date
Application number
AT00904979T
Other languages
English (en)
Inventor
Peter Jungblut
Stefan Kaufmann
Ulrich Schaible
Hans Mollenkopf
Baerbel Raupach
Ursula Zimny-Arndt
Stephanie Lamer
Jens Mattow
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Application granted granted Critical
Publication of ATE366583T1 publication Critical patent/ATE366583T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT00904979T 1999-01-29 2000-01-28 Identifizierung von spezifischen differenziell exprimierten antigenen aus mycobacterium und medizinische verwendung der mycobakteriumproteine rv0068 und rv3407 ATE366583T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99101590 1999-01-29

Publications (1)

Publication Number Publication Date
ATE366583T1 true ATE366583T1 (de) 2007-08-15

Family

ID=8237440

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00904979T ATE366583T1 (de) 1999-01-29 2000-01-28 Identifizierung von spezifischen differenziell exprimierten antigenen aus mycobacterium und medizinische verwendung der mycobakteriumproteine rv0068 und rv3407

Country Status (10)

Country Link
US (1) US7772386B1 (de)
EP (1) EP1146889B1 (de)
JP (1) JP2002534994A (de)
AT (1) ATE366583T1 (de)
AU (1) AU2667600A (de)
CA (1) CA2361246C (de)
DE (1) DE60035485T2 (de)
DK (1) DK1146889T3 (de)
ES (1) ES2288842T3 (de)
WO (1) WO2000044392A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2135947A1 (de) * 2008-06-17 2009-12-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Antagonisten bakterieller Sequenzen
ITRM20100411A1 (it) * 2010-07-23 2012-01-24 Massimo Amicosante Uso di sequenze amminoacidiche da mycobacterium tuberculosis o dei loro corrispondenti acidi nucleici per la diagnosi e la prevenzione di infezione tubercolare, relativo kit diagnostico e vaccino.
US9726667B2 (en) * 2014-03-07 2017-08-08 Institute For Systems Biology Point of care assays to detect the status of tuberculosis infection
US11679150B2 (en) 2020-03-03 2023-06-20 The United States Of America, As Represented By The Secretary Of Agriculture Mycoplasma bovis vaccine product
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
KR102405798B1 (ko) * 2020-06-22 2022-06-08 주식회사 미코라파 Rv2882c-Rv2005c 융합 단백질을 포함하는 결핵 면역 치료용 조성물
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
KR102878370B1 (ko) * 2022-06-17 2025-10-31 주식회사 미코라파 면역활성 부위 융합 단백질을 포함하는 결핵 백신 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2624759B2 (ja) * 1988-03-30 1997-06-25 味の素株式会社 Ｂｃｇ菌由来のｍｐｂ６４蛋白及びその製造法
FR2752425B1 (fr) * 1996-08-19 1998-11-13 Pasteur Institut Fragments d'acides nucleiques specifiques de mycobacteries membres du complexe m. tuberculosis et leurs applications pour la detection et le diagnostic differentiel des membres du complexe m. tuberculosis

Also Published As

Publication number Publication date
DE60035485T2 (de) 2008-03-20
EP1146889A2 (de) 2001-10-24
AU2667600A (en) 2000-08-18
WO2000044392A2 (en) 2000-08-03
CA2361246C (en) 2013-04-16
US7772386B1 (en) 2010-08-10
ES2288842T3 (es) 2008-02-01
EP1146889B1 (de) 2007-07-11
WO2000044392A3 (en) 2000-12-07
CA2361246A1 (en) 2000-08-03
DK1146889T3 (da) 2007-10-22
JP2002534994A (ja) 2002-10-22
DE60035485D1 (de) 2007-08-23

Similar Documents

Publication Publication Date Title
Brandt et al. New multi-determinant strategy for a group A streptococcal vaccine designed for the Australian Aboriginal population
Hanff et al. Humoral immune response in human syphilis to polypeptides of Treponema pallidum
JP4283872B2 (ja) 微生物蛋白質と、この蛋白質を産生する微生物と、該蛋白質のワクチンおよび結核検出での利用
DE60139690D1 (de) Immunisierung gegen chlamydia pneumoniae
BRPI0208301A8 (pt) vacinas de ácido nucléico para prevenção de infecção por flavivírus
FI895050A0 (fi) Diagnostiska preparat och vaccin foer mykobakterier i folkhaelso-, medicinsk och veterinaermedicinsk praxis.
ITFI920052A1 (it) Proteina estratta da ceppi citotossici di helicobacter pylori, gene che la esprime, uso della proteina come vaccino o diagnostico.
ATE526994T1 (de) Mtb32a antigen aus mycobakterium tuberculosis mit inaktivierter protease aktivität und fusionsproteine die das antigen enthalten
Huang et al. Immunization with cell‐free‐generated vaccine protects from Porphyromonas gingivalis‐induced alveolar bone loss
DE60144201D1 (de) Lawsonia intracellularis Impfstoff
Cho et al. Extracellular vesicle-associated antigens as a new vaccine platform against scrub typhus
ATE366583T1 (de) Identifizierung von spezifischen differenziell exprimierten antigenen aus mycobacterium und medizinische verwendung der mycobakteriumproteine rv0068 und rv3407
US7862828B2 (en) Allergy vaccines containing hybrid polypeptides
KR100366482B1 (ko) 백신으로서 정제된 분류가능하지 않은 헤모필루스 인프루엔자 p5단백질, 및 그의 정제방법
Chelliah et al. Potential DNA vaccine for haemorrhagic septiceamia disease
WO2004020609A3 (en) Streptococcus pneumoniae antigens for diagnosis, treatment and prevention of active infection
DE68923286D1 (de) Impfstoffe und testsätze für haemophilus influenzae.
EP2391640B1 (de) Clostridium-chauvoei-polypeptid, dna, die das polypeptid kodiert, und vakzin, das das polypeptid umfasst
Tafuku et al. Japanese encephalitis virus structural and nonstructural proteins expressed in Escherichia coli induce protective immunity in mice
Nassrullah et al. Cloning, Sequencing and Expression of the Brucella Melitensis Novel Lomr Protein.
Asma et al. Analysis of outer membrane proteins of Pasteurella multocida strains isolated from buffaloes affected with hemorrhagic septicemia
Ragavendhar et al. Sequence analysis, 3-dimensional protein modelling and epitope prediction of Oma87 gene originating from Pasteurella multocida isolate of sheep
DE602005020428D1 (de) Sequenzen des schnabel- und federkrankheit-virus, zusammensetzungen und impfstoffe und deren verwendung in der therapie, der diagnose und in assays
BR102019004148A2 (pt) Polipeptídeo ligbnid de leptospira spp. para uso como imunobiológico
WO2022208158A1 (es) Vacunas efectivas para la prevención del botulismo

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties